Investigating a treatment to prevent heart rhythm issues caused by pressure overload in the heart.
Official title: Therapeutic Modulation of Atrial Remodeling
Funded at New York University School of Medicine · NIH-11117155 · Data updated 2026-11-12
This study is looking at how a vitamin A derivative might help people with atrial fibrillation by improving heart function and reducing inflammation caused by high blood pressure in the heart.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $695,882 |
| NIH project number | 5R01HL171989-02 |
| Project ID | NIH-11117155 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults with atrial fibrillation or conditions that cause increased pressure in the heart.
✕Less likely to help
Patients without atrial fibrillation or related heart conditions may not benefit from this research.
What this research studies
This research focuses on atrial fibrillation (AF), a serious heart condition that can lead to strokes and other health problems. The study aims to explore how a vitamin A derivative, all-trans retinoic acid (ATRA), can prevent and reverse changes in the heart's left atrium caused by high pressure. By analyzing gene expression and using advanced sequencing techniques, the researchers hope to identify how ATRA can normalize heart function and reduce inflammation. Patients with conditions that lead to increased heart pressure may benefit from this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat atrial fibrillation and improve heart health.
How similar studies have gone: Previous research has shown that ATRA can improve heart conduction in patients with acute promyelocytic leukemia, suggesting potential for success in treating atrial remodeling.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Park, David S — New York University School of Medicine
- Study coordinator: Park, David S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.